Literature DB >> 17414408

Successful medical treatment of cutaneous aspergillosis in a premature infant using liposomal amphotericin B, voriconazole and micafungin.

Roberto P Santos1, Pablo J Sánchez, Asuncion Mejias, Daniel K Benjamin, Thomas J Walsh, Sanjay Patel, Hasan S Jafri.   

Abstract

Treatment options for primary cutaneous aspergillosis in neonates are limited by the lack of pharmacokinetic and safety data of newer antifungal agents that are effective against Aspergillus spp. We report the successful treatment of cutaneous aspergillosis in an extremely low-birth-weight preterm infant with liposomal amphotericin B, voriconazole and micafungin, and provide pharmacokinetic profiles for voriconazole and micafungin.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17414408     DOI： 10.1097/01.inf.0000258698.98370.89

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN： 0891-3668            Impact factor:   2.129


  14 in total

Review 1.  Pharmacokinetics of antifungal agents in children.

Authors:  Kevin Watt; Daniel K Benjamin; Michael Cohen-Wolkowiez
Journal:  Early Hum Dev       Date:  2011-02-01       Impact factor: 2.079

2.  Therapeutic monitoring of voriconazole in children less than three years of age: a case report and summary of voriconazole concentrations for ten children.

Authors:  Elizabeth H Doby; Daniel K Benjamin; Anne J Blaschke; Robert M Ward; Andrew T Pavia; Paul L Martin; Timothy A Driscoll; Michael Cohen-Wolkowiez; Cassandra Moran
Journal:  Pediatr Infect Dis J       Date:  2012-06       Impact factor: 2.129

3.  [Primary cutaneous aspergillosis in an extremely low birth weight preterm infant].

Authors:  D Klotz; H Kneitz; J Wirbelauer
Journal:  Hautarzt       Date:  2013-09       Impact factor: 0.751

4.  A review of clinical experience with newer antifungals in children.

Authors:  Renee M Fallon; Jennifer E Girotto
Journal:  J Pediatr Pharmacol Ther       Date:  2008-07

Review 5.  Triazole use in the nursery: fluconazole, voriconazole, posaconazole, and ravuconazole.

Authors:  Kevin Watt; Paolo Manzoni; Michael Cohen-Wolkowiez; Stefano Rizzollo; Elena Boano; Evelyne Jacqz-Aigrain; Daniel K Benjamin
Journal:  Curr Drug Metab       Date:  2013-02       Impact factor: 3.731

6.  Pharmacodynamics of amphotericin B deoxycholate, amphotericin B lipid complex, and liposomal amphotericin B against Aspergillus fumigatus.

Authors:  Zaid Al-Nakeeb; Vidmantas Petraitis; Joanne Goodwin; Ruta Petraitiene; Thomas J Walsh; William W Hope
Journal:  Antimicrob Agents Chemother       Date:  2015-02-23       Impact factor: 5.191

7.  Primary cutaneous aspergillosis in a preterm neonate.

Authors:  Bjarte Rogdo; Christian Kahlert; Pierre André Diener; John Micallef
Journal:  BMJ Case Rep       Date:  2014-09-01

8.  The pharmacokinetics and pharmacodynamics of micafungin in experimental hematogenous Candida meningoencephalitis: implications for echinocandin therapy in neonates.

Authors:  William W Hope; Diana Mickiene; Vidmantas Petraitis; Ruta Petraitiene; Amy M Kelaher; Joanna E Hughes; Margaret P Cotton; John Bacher; James J Keirns; Donald Buell; Gloria Heresi; Daniel K Benjamin; Andreas H Groll; George L Drusano; Thomas J Walsh
Journal:  J Infect Dis       Date:  2008-01-01       Impact factor: 5.226

Review 9.  Treatment and prophylaxis of invasive candidiasis.

Authors:  Nidhi Tripathi; Kevin Watt; Daniel K Benjamin
Journal:  Semin Perinatol       Date:  2012-12       Impact factor: 3.300

10.  Successful Treatment of Candida parapsilosis Fungemia in Two Preterms with Voriconazole.

Authors:  Emel Altuncu; Hulya Bilgen; Ahmet Soysal; Eren Ozek
Journal:  Case Rep Pediatr       Date:  2015-06-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.